CY1107142T1 - Τυποποιηση που περιλαμβανει fulvestrant - Google Patents

Τυποποιηση που περιλαμβανει fulvestrant

Info

Publication number
CY1107142T1
CY1107142T1 CY20081100057T CY081100057T CY1107142T1 CY 1107142 T1 CY1107142 T1 CY 1107142T1 CY 20081100057 T CY20081100057 T CY 20081100057T CY 081100057 T CY081100057 T CY 081100057T CY 1107142 T1 CY1107142 T1 CY 1107142T1
Authority
CY
Cyprus
Prior art keywords
oestra
17beta
triene
nonyl
diol
Prior art date
Application number
CY20081100057T
Other languages
English (en)
Inventor
Paul Richard Gellert
Alison Margaret Potts
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1107142T1 publication Critical patent/CY1107142T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Η εφεύρεση αναφέρεται σε μία φαρμακευτική τυποποίηση, που κατά προτίμηση προσαρμόζεται για χορήγηση με έγχυση, που περιέχει την ένωση 7a-[9-(4,4,5,5,5-πενταφθοροπεντυλσουλφινυλ)εννεανυλ]οιστρα-1,3,5(10)-τριένιο-3,17β-διόλη κι ένα αντιοξειδωτικό, ειδικότερα σε μία τυποποίηση που προσαρμόζεται για χορήγηση με έγχυση που περιέχει την ένωση 7a-[9-(4,4,5,5,5-πενταφθοροπεντυλσουλφινυλ)εννεανυλ]οιστρα-1,3,5(10)τριένιο-3,17β-διόλη σε διάλυμα σ' ένα όχημα ρικινελαϊκού εστέρα που περιλαμβάνει ένα αντιοξειδωτικό.
CY20081100057T 2001-07-07 2008-01-15 Τυποποιηση που περιλαμβανει fulvestrant CY1107142T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116620.6A GB0116620D0 (en) 2001-07-07 2001-07-07 Formulation
EP02745579A EP1409021B1 (en) 2001-07-07 2002-07-03 Formulation comprising fulvestrant

Publications (1)

Publication Number Publication Date
CY1107142T1 true CY1107142T1 (el) 2012-10-24

Family

ID=9918096

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100057T CY1107142T1 (el) 2001-07-07 2008-01-15 Τυποποιηση που περιλαμβανει fulvestrant

Country Status (12)

Country Link
US (1) US20040175402A1 (el)
EP (1) EP1409021B1 (el)
JP (1) JP4295087B2 (el)
AT (1) ATE378070T1 (el)
AU (1) AU2002317298A1 (el)
CY (1) CY1107142T1 (el)
DE (1) DE60223542T2 (el)
DK (1) DK1409021T3 (el)
ES (1) ES2294146T3 (el)
GB (1) GB0116620D0 (el)
PT (1) PT1409021E (el)
WO (1) WO2003006063A2 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188557A1 (en) * 2003-05-23 2006-08-24 Hisamitsu Pharmaceutical Co., Inc. Prepartaion for external percutaneous administration containing non-steroidal anti-inflammatory drug and interleukin-1 alpha production inhibitor
JP5133064B2 (ja) * 2005-01-05 2013-01-30 國防教育研究基金会 ウリジン２リン酸（ｕｄｐ）−グルクロン酸転移酵素２ｂ（ｕｇｔ２ｂ）の抑制剤及び促進剤
JP2009509942A (ja) * 2005-09-26 2009-03-12 ホスピラ・オーストラリア・ピーティーワイ・リミテッド フルベストラント製剤
WO2007044662A2 (en) * 2005-10-05 2007-04-19 Sicor, Inc. Separation of fulvestrant isomers
CN102014925B (zh) 2008-03-07 2013-02-06 赛多斯有限责任公司 氟维司群配制剂
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
MX2013013558A (es) 2011-05-20 2013-12-16 Capital Business Y Gestion De Finanzas S L Composicion farmaceutica.
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
WO2015157752A1 (en) * 2014-04-11 2015-10-15 Sam Houston State University Dialkyl trisulfides and formulations of dialkyl trisulfides for use as a cyanide antidote
CN108159055A (zh) * 2018-01-04 2018-06-15 西安力邦医药科技有限责任公司 治疗乳腺癌的长效递药系统、其制备方法及应用
CN111465398A (zh) * 2018-01-31 2020-07-28 富士胶片株式会社 注射用制剂的制造方法
CN113694017B (zh) * 2020-05-11 2024-04-02 鲁南制药集团股份有限公司 一种氟维司群注射制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
DE60223542T2 (de) 2008-11-13
EP1409021B1 (en) 2007-11-14
JP4295087B2 (ja) 2009-07-15
EP1409021A2 (en) 2004-04-21
PT1409021E (pt) 2008-01-11
WO2003006063A2 (en) 2003-01-23
ES2294146T3 (es) 2008-04-01
US20040175402A1 (en) 2004-09-09
WO2003006063A3 (en) 2003-05-15
GB0116620D0 (en) 2001-08-29
DE60223542D1 (de) 2007-12-27
DK1409021T3 (da) 2008-02-11
JP2004521151A (ja) 2004-07-15
ATE378070T1 (de) 2007-11-15
AU2002317298A1 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
CY1107142T1 (el) Τυποποιηση που περιλαμβανει fulvestrant
BG106833A (en) Fulvestrant formulation
IL188774A0 (en) Compositions for delivery of drug combinations
NO20034149D0 (no) Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel
HK1077208A1 (en) Topical composition containing at least one vitminD or one vitamin D analogue and at least one cort icosteroid
NZ527157A (en) Compositions for delivering bisphosphonates
HN2002000247A (es) Derivados de sulfonamida
WO2004093795A3 (en) Compositions for delivery of drug combinations
GB0122318D0 (en) Organic compounds
MY148680A (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
BG106030A (en) Pharmaceutical composition
ATE329897T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
MXPA05008913A (es) Formulacion oftalmica estable que contiene antibiotico y corticoesteroide.
DK1121127T3 (da) Orale farmaceutiske sammensætninger, som indeholder buprenorphin
NO20064808L (no) Orale matrixformuleringer med licarbazepin
EE05415B1 (et) Ravimi manustamise vahend, eriti androgeenide manustamiseks
MXPA04000028A (es) Formulacion farmaceutica para la administracion intramuscular de fulvestrant.
AU2001261516A1 (en) Semi-solid delivery vehicle and pharmaceutical compositions
WO2004004639A3 (en) A novel stable formulation
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
SE9902742D0 (sv) New pharmaceutical formultion
EP1232740A3 (en) Hair-growing agent
WO2004078677A3 (en) Enhanced delivery of sphingolipids
GB0128071D0 (en) Medicament
WO2004058141A3 (en) An agent for controlling bcl-2 expression comprising ginsenoside f1 as an active component